Unilife Corp

Unilife — Shareholder Meeting (December 2012)

32 slides from Unilife's shareholder meeting presentation, Dec 3, 2012

  1. Slide 1: Annual General Meeting of Stockholders

    Annual General Meeting of Stockholders November 29, 2012 NASDAQ (UNIS) and ASX (UNS) Exhibit 99.1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-lo

  3. Slide 3: Chairman's Welcome

    Chairman's Welcome Jim Bosnjak OAM NASDAQ (UNIS) and ASX (UNS)

  4. Slide 4: Introducing our Board of Directors In Attendance

    Introducing our Board of Directors In Attendance Alan Shortall CEO Executive Director since 2002 Mary Kate Wold, J.D. Non-Executive Director since 2010 Chair of Strategic Partnerships Committee John Lund, CPA Non-Executive Director since 2009 Chair of Audit Committee William Galle Non-Executive Dire

  5. Slide 5: Introducing our Board of Directors Apologies

    November 29, 2012 Introducing our Board of Directors Apologies Jeff Carter MApp. BFin Non-Executive Director since 2006 Based in Australia Marc Firestone, J.D. Non-Executive Director since 2010 Chair of Nominating and Corporate Governance Committee Chair of Audit Committee

  6. Slide 6: Agenda

    Agenda Confirmation of Quorum Resolutions Presentation from the CEO Questions Confirmation of Results Other Business

  7. Slide 7: Resolutions

    Resolutions November 29, 2012 1.1 Elect Director Slavko James Joseph Bosnjak 1.2 Elect Director Jeff Carter 1.3 Elect Director William Galle 1.4 Elect Director John Lund 1.5 Elect Director Mary Katherine Wold 1.6 Elect Director Alan D. Shortall 2 Ratify Auditors 3 Advisory Vote to Ratify Named Execu

  8. Slide 8: Confirmation of Quorum

    Confirmation of Quorum Unilife's quorum requirement is one-third of outstanding shares being represented either in person or by proxy At least 54% of the total outstanding shares entitled to vote have been received and are represented by person or proxy

  9. Slide 9: Presentation by Mr. Alan Shortall, CEO

    Presentation by Mr. Alan Shortall CEO NASDAQ (UNIS) and ASX (UNS)

  10. Slide 10: Broad, Expanding Portfolio of Device Platforms

    November 29, 2012 Broad, Expanding Portfolio of Device Platforms Prefilled Syringes $2B market (12-15% CAGR) Drug Reconstitution $500MM (20-30%+ CAGR) Auto-Injectors $1B market (15-25% CAGR) Injection Pumps $500MM (30-50%+ CAGR) Targeted Delivery $250MM (20-30% CAGR) Unifill Syringe EZMix (tm) Lisa

  11. Slide 11: Diversified, Expanding Base of Customers

    November 29, 2012 November 29, 2012 Diversified, Expanding Base of Customers

  12. Slide 12: A Glimpse into our Commercial Pipeline

    A Glimpse into our Commercial Pipeline Device Platform No. of programs No. of customers No. programs with 2013 revenues targeted Cumulative peak annual sales ($MM) Prefilled syringes 10 10 5 $315 Bolus Injectors (pumps) 8 6 4 $372 Auto-injectors 3 3 1 $65 Drug reconstitution 5 5 1 $120 Targeted deli

  13. Slide 13: Prefilled Syringes with Integrated Safety

    Prefilled Syringes with Integrated Safety November 29, 2012 Unifill(r) syringe Unifill(r) Select Automatic Retraction USP-Compliant Per Standard Handling Intuitive Steps of Use Auto Needle Lockout A unique best-in-class platform to serve the delivery needs of virtually all prefilled drugs and vaccin

  14. Slide 14: Unifill Platform - Commercial Pipeline

    Unifill Platform - Commercial Pipeline Device Drug Status Next Value Event First Targeted Revenue Target Launch Peak Annual Sales Per Contract $MM Customer Designation Unifill Approved Supply contract 2013 2014 $70 A Unifill Approved Regulatory submission 2013 2014 $15 B Unifill Late-Stage Clinical

  15. Slide 15: Liquid / Dry Combinations Drug Reconstitution Delivery Systems

    Liquid / Dry Combinations Drug Reconstitution Delivery Systems 2-Step Reconstitution Automatic Retraction Intuitive Steps of Use Uniquely Ventless A game-changing technology for the reconstitution and delivery of liquid or dry drug combination therapies EZMix(tm) syringe EZMix(tm) Select

  16. Slide 16: Drug Reconstitution - Commercial Pipeline

    Drug Reconstitution - Commercial Pipeline Device Drug Status Next Value Event First Target Revenues Target Launch Peak Annual Sales Per Contract $MM Customer Designation EZMix Late-stage Clinical development contract 2013 2015 20 E EZMix Late-stage Clinical development contract 2014 2017 20 D EZMix

  17. Slide 17: Auto-Injectors

    Auto-Injectors Our elegant, intuitive auto-injectors have true end-of-dose indicators and can address specific drug and patient needs LISA Reusable Auto- Injector RITA Disposable Auto- Injector Today shipping LISA to a large cap customer as prelude to Clinical development contract

  18. Slide 18: Auto-Injectors - Commercial Pipeline

    Auto-Injectors - Commercial Pipeline A selection of our active programs Drug Status Next Value Event First Target Revenues Target Launch Peak Annual Sales Per Contract $MM Customer Designation LISA Late-stage Clinical development contract 2013 2015 20 D LISA Late-stage Clinical development contract

  19. Slide 19: Bolus Injectors and Infusion Pumps

    Bolus Injectors and Infusion Pumps November 29, 2012 From 1mL - 30mL dose volumes Suitable for Bolus or Rate-Based Therapies Standard Handling and Materials in Fluid Path Safe, Ergonomic and Intuitive Design Many Customization Options A platform of wearable, disposable devices for the long-duration

  20. Slide 20: Injection Pumps - Commercial Pipeline

    Injection Pumps - Commercial Pipeline A Selection of our Most Active Programs Drug-Status Next Value Event First Target Revenues Target Launch* Peak Annual Sales Per Contract $MM Customer Designation Late-stage Clinical development contract 2013 2015 75 C Late-stage Clinical development contract 201

  21. Slide 21: Targeted Delivery Systems

    Targeted Delivery Systems November 29, 2012 Depot-ject(tm) Ocu-ject(tm) Innovative devices to accurately inject novel therapies requiring localized or targeted delivery of doses to the eye or other organs

  22. Slide 22: Targeted Delivery Systems - Commercial Pipeline

    Targeted Delivery Systems Device Drug Status Next Value Event First Target Revenues Target Launch Peak Annual Sales Per Contract $MM Customer designation Ocu-ject Late-stage Clinical development contract 2013 2015 $20 D Ocu-ject Late-stage Clinical development contract 2014 2016 $20 P Organ delivery

  23. Slide 23: Summary of our Commercial Pipeline

    Summary of our Commercial Pipeline More than 30 active programs with 20 customers now at an advanced status with significant value events in progress More than a dozen programs covering every device platform to begin generating near-term revenues in 2013 Clinical development programs for all Unilife

  24. Slide 24: Summary

    Summary Unilife has never been in a stronger position than today The commercial potential for Unilife is greater than ever Business strategy is being fully executed, in most cases ahead of schedule and resonating strongly with customers Building tremendous value that will be recognized via a series

  25. Slide 25: Questions

    a oa Questions uniure?

  26. Slide 26: Consider and Vote for Matters set forth in Proxy Statement

    Consider and Vote for Matters set forth in Proxy Statement NASDAQ (UNIS) and ASX (UNS)

  27. Slide 27: Election of Directors

    Election of Directors Item 1. For For Withheld Withheld Item 1.1 Jim Bosnjak 36,950,413 96.54% 1,324,051 3.46% Item 1.2 Jeff Carter 36,414,906 95.14% 1,859,558 4.86% Item 1.3 William Galle 37,388,860 97.69% 885,604 2.31% Item 1.4 John Lund 37,330,534 97.53% 943,930 2.47% Item 1.5 Mary Kate Wold 37,8

  28. Slide 28: Item 2. Ratification of KPMG LLP as Auditor

    Item 2. Ratification of the appointment of KPMG LLP as the Corporation's independent registered public accounting firm for Fiscal Year 2013 For Against Abstain Item 2. 44,650,235 (99.1%) 344,269 (0.76%) 64,985 (0.14%)

  29. Slide 29: Item 3. Advisory Vote on Executive Compensation

    Item 3. For Against Abstain Item 3. 26,468,008 (69.15%) 11,509,238 (30.07%) 297,218 (0.78%) To consider and act on an advisory vote regarding the approval and compensation paid to certain executive officers

  30. Slide 30: Item 4. Ratification of Issuance and Sale of Common Stock

    Item 4. For Against Abstain Item 4. 37,306,982 (97.48%) 855,402 (2.23%) 112,080 (0.23%) To consider and act on the ratification of the issuance and sale by the Company of 6,154,000 shares of the Company's common stock in June 2012

  31. Slide 31: Other Business

    Other Business NASDAQ (UNIS) and ASX (UNS)

  32. Slide 32: Close of Meeting

    Close of Meeting NASDAQ (UNIS) and ASX (UNS)

Unilife — Shareholder Meeting (December 2012) on 6ix